News
Fresh from ASH 2021: Promising results of the combination of azacitidine with venetoclax and magrolimab in the treatment of AML
Dr. Naval Daver and his colleagues from the Anderson Cancer Center in Houston presented an oral report during the December congress of the American Society of Hematology (ASH 2021) about a phase Ib/II study that evaluated the effects of the combination of azacitidine (AZA) + venetoclax (VEN) + magrolimab (magro) in various types of patients with acute myeloid leukemia (AML) – newly diagnosed in older or unfit individuals, high-risk, or relapsed/refractory cases (R/R AML).
How Diabetes Shortens Life or Mortality of Patients with Type 2 Diabetes
Type 2 diabetes mellitus (DM) has a significant impact on overall mortality across age categories.…
Less is Sometimes More – How Generic Substitution Can Affect Patient Adherence
It is undisputed that the use of generic drugs saves the healthcare system significant costs.…
Limits of Glycated Hemoglobin and the Importance of Other Glycated Proteins
Glycated hemoglobin is a gold standard in the diagnosis and management of diabetes treatment.…
Treatment of Cough in Clinical Practice: Which Preparations Are Suitable and When?
In clinical practice, we differentiate the treatment of non-productive and moist productive cough.…
Quo vadis, erdostein? Or the current and future potential of erdosteine in practice
Erdosteine has a well-established place in the therapy of acute respiratory diseases in children.…
What is the effectiveness of levodropropizine in the treatment of children's cough?
Levodropropizine represents an effective and safe option for the treatment of acute irritating…
Effects of Progestins in Combination with EE on Endothelial Function, Lipid Levels, and Oxidative Stress in Women with Endometriosis
Studies have shown endothelial dysfunction and increased oxidative stress in women with…
Alzheimer's Disease – Another Pandemic on the Horizon?
Due to the COVID-19 pandemic, other current problems often get pushed into the background. One of…
Current Treatment Options for Multiple Myeloma
Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. Thanks to…
Conferences
News from the world of medicine
11. 6.
All conferences
Popular this week
- Multiple system atrophy
- Intermittent Fasting May Carry Significant Health Risks
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Tuberous Sclerosis
- A device the size of a matchbox will help treat obstructive sleep apnea